CVE:MDP

Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis

C$7.75
-0.40 (-4.91%)
(As of 06/16/2021)
Today's Range
C$7.70
C$8.14
50-Day Range
C$7.75
C$7.75
52-Week Range
C$2.80
C$9.75
Volume
40,981 shs
Average Volume
68,619 shs
Market Capitalization
C$148.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$3.18
MDP stock logo

About Medexus Pharmaceuticals Stock (CVE:MDP)

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.

MDP Stock Price History

MDP Stock News Headlines

Medexus Pharmaceuticals Inc (P731.BE)
See More Headlines
Receive MDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$3.18
High Stock Price Target
C$4.00
Low Stock Price Target
C$2.35
Potential Upside/Downside
-59.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$108.29 million
Cash Flow
C$0.62 per share
Book Value
C$0.38 per share

Miscellaneous

Free Float
N/A
Market Cap
C$148.54 million
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Kenneth d'Entremont
    CEO & Director
  • Mr. Roland Boivin
    Chief Financial Officer
  • Mr. Bill Poncy
    Sr. VP of Commercial Operations - United States
  • Mr. Brian Peters
    VP of Sales & Marketing - United States
  • Ms. Tina Byers CFA
    Exec. of Investor Relations
  • Mr. Michael Pine
    Sr. VP of Bus. Devel. & Strategy
  • Mr. Michael David Adelman (Age 50)
    Gen. Mang., U.S. Operations

MDP Stock Analysis - Frequently Asked Questions

Should I buy or sell Medexus Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDP shares.
View MDP analyst ratings
or view top-rated stocks.

What is Medexus Pharmaceuticals' stock price target for 2024?

2 analysts have issued twelve-month price targets for Medexus Pharmaceuticals' stock. Their MDP share price targets range from C$2.35 to C$4.00. On average, they expect the company's share price to reach C$3.18 in the next twelve months. This suggests that the stock has a possible downside of 59.0%.
View analysts price targets for MDP
or view top-rated stocks among Wall Street analysts.

How have MDP shares performed in 2024?

Medexus Pharmaceuticals' stock was trading at C$7.75 at the start of the year. Since then, MDP shares have increased by 0.0% and is now trading at C$7.75.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Medexus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medexus Pharmaceuticals investors own include Gatekeeper Systems (GSI), Enghouse Systems (ENGH), Ag Growth International (AFN).

How do I buy shares of Medexus Pharmaceuticals?

Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:MDP) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners